Is it really impossible to stop taking canafenib/encofenib?

Encorafenibas an oral small molecule inhibitor targetingBRAF V600 mutation, has been widely used to treat a variety of solid tumors including melanoma, colorectal cancer and non-small cell lung cancer. During the treatment process, many patients will be concerned about a core question: once they start taking canafenib, do they have to take it for life and cannot stop taking it? There is no absolute yes or no to this question, but from a clinical perspective, continued treatment with canafenib is critical to maintaining tumor control.

The mechanism of Canafenib is to continuously inhibit the BRAF mutation signaling pathway, thereby blocking the growth and spread of tumor cells. This type of targeted drugs does not pursue "short-term killing" like traditional chemotherapy, but emphasizes "long-term suppression." Clinical research and actual medication experience show that if patients rashly stop taking medication without clear evidence of drug resistance, disease progression or serious adverse reactions, it may cause tumor rebound or even worsening, affecting survival time and quality of life. Especially in combination treatment modes, such as when canafenib is combined with bimetinib or cetuximab, the combined inhibitory mechanism relies more on continued drug exposure to maintain efficacy.

Of course, not all patients have to take medication "indefinitely". Once intolerable toxic reactions such as severe hepatotoxicity, QT interval prolongation or skin reactions occur, doctors will consider temporarily discontinuing the drug or reducing the dose according to the condition. In addition, if the patient experiences long-term complete remission, under specific evaluation, discontinuation of drug observation may be considered in some cases, but this must be strictly performed under the guidance of oncologists and requires high-frequency reexamination and monitoring.

In general, whether to discontinue canafenib is not something that patients can decide on their own. Its use is essentially a "chronic disease management" anti-cancer strategy, which emphasizes continuity, stability and individualized adjustment. For most BRAF mutation-positive patients, maintaining drug continuity is the core guarantee for achieving long-term remission and extending survival.

Reference materials:https://www.braftovi.com/